The STIX formulation appears to be a massive upgrade in terms of...

The STIX formulation appears to be a massive upgrade in terms of usability, portability and the removal of artificial colours and preservatives over the original Daybue formulation.

Being able to combine STIX with a patient's favourite beverage must be a godsend for carers where change would not often be easily welcomed.

No longer requiring the drug to be refrigerated eases transportation difficulties for carers and transportation costs for Acadia. The lack of needing to refrigerate the drug was already an inherent advantage of NNZ-2591 over Trifinitide.

The removal of artificial colours and preservatives will perhaps ease the minds of carers by reducing the amount of non-essential chemicals given to their loved ones while also potentially reducing any adverse reactions to said chemicals (adverse reactions to the colours and preservatives in Daybue have not be proven.)

I'm looking forward to seeing how many discontinued users of Daybue choose to try STIX now that it is more flexible and portable compared to the original formulation, boosting the total number of patients.

Hopefully this only strengthens the application for Daybue/STIX being approved in Europe and we receive some good news on the matter in the coming months.

Good luck to all involved.